Determinant of Fetal Growth Retardation After Sleeve Gastrectomy: Involvement of Ghrelin

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Aug 3, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at pregnant women who have had a specific type of weight-loss surgery called sleeve gastrectomy (SG). The main goal is to see if changes in a hormone called ghrelin, which helps control hunger, are linked to slower growth in babies while they are still in the womb. Researchers want to find out if there is a relationship between the levels of ghrelin in mothers and the weight of their babies at birth.

To participate in this study, women need to have had sleeve gastrectomy surgery, be pregnant between 3 to 6 months, and be carrying only one baby. They will also need to come in for a nutritional assessment. Unfortunately, women with twin pregnancies, those who have had other types of weight-loss surgery, or those with other specific health issues may not be eligible. If someone joins the study, they can expect to provide information about their health and possibly have their hormone levels tested. This trial is currently recruiting participants and aims to better understand how weight-loss surgery may affect pregnancy outcomes.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Woman previously operated of sleeve gastrectomy
• • Pregnant from 3 to 6 months
• • Having a mono-fetal pregnancy
• • Coming to consult in day hospital for a nutritional assessment
• Exclusion Criteria:
• • Twin pregnancy
• • Identified cause of IUGR apart from those related to sleeve gastrectomy
• • Woman who has undergone another bariatric surgery technique
• • Lack of individual information and collection of the consent form
• • Problems of understanding
• • Lack of affiliation to a social security scheme or state medical aid
• • Patient benefiting from a legal protection measure (with guardians or curators)